| Range | 313.00 - 315.80 |
| 52 week | 158.50 - 340.00 |
| Open | 315.80 |
| Vol / Avg. | 116,136.00/292,962.00 |
| Mkt cap | 752.81M* |
| P/E | 23.43 |
| Div/yield | 2.21* |
| EPS | 0.13* |
| Shares | 240.20M |
| Beta | - |
| Inst. own | - |
| *GBP |
|
|
| Q1 (Mar '13) | 2012 | |
| Net profit margin | 1.29% | 2.60% |
| Operating margin | 2.41% | 3.69% |
| EBITD margin | - | 5.14% |
| Return on average assets | 2.27% | 4.52% |
| Return on average equity | 6.26% | 11.80% |
| Employees | 4,612 | - |
| Carbon Disclosure Rating | - | - |
| Liam M. FitzGerald | Chief Executive, Executive Director | |
| Chris Corbin | Managing Director - Sales, Marketing & Medical division, Executive Director | |
| Alan Ralph | Chief Financial Officer, Executive Director | |
| Mike Gannon | Company Secretary | |
| Peter Gray | Non-Executive Independent Chairman of the Board | |
| Barry McGrane | Non-Executive Director | |
| Christopher Brinsmead | Non-Executive Independent Director | |
| Hugh Friel | Non-Executive Independent Director | |
| Gary W. McGann | Senior Independent Non-Executive Director |